Skip to content

Pharmacy

Glenmark cleared to market Evista generic

Glenmark cleared to market Evista generic

Glenmark Pharmaceuticals Inc. USA has received final approval from the Food & Drug Administration for raloxifene hydrochloride tablet. Glenmark said Wednesday that its raloxifene product is a generic equivalent of Evista tablets (60 mg) from Eli Lilly and Co.

Innovation collaborates on pharmacy operations paper

Innovation collaborates on pharmacy operations paper

The Advanced Systems Division of pharmacy automation provider Innovation partnered with the Binghamton University Watson Institute for Systems Excellence (BU WISE) on a thesis paper published in the journal Expert Systems With Applications (ESWA).

Camber rolls out Zocor, Valcyte generics

Camber rolls out Zocor, Valcyte generics

Camber Pharmaceuticals has launched two new generic drug products. The company has released simvastatin tablets, a cholesterol-lowering medication, in strengths of 5 mg, 10 mg, 20 mg, 40 mg and 80 mg.

American Associated Pharmacies to acquire PIPCo

American Associated Pharmacies to acquire PIPCo

Pharmacy cooperative American Associated Pharmacies (AAP) plans to acquire Partners in Pharmacy Cooperative (PIPCo). Financial terms of the acquisition weren’t disclosed. AAP said late Monday that PIPCo will be rebranded and operated under the AAP banner.

Rite Aid’s Health Dialog brings Nurse Line to L.A. Care

Rite Aid’s Health Dialog brings Nurse Line to L.A. Care

Rite Aid Corp. subsidiary Health Dialog will provide members of L.A. Care Health Plan, the largest U.S. public health plan, with round-the-clock telephone access to registered nurses, including from select Rite Aid drug stores. Under the agreement, announced Monday, L.A.

Senate OK’s key drug abuse legislation

Senate OK’s key drug abuse legislation

The U.S. Senate has passed the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 (S. 483), which is seen as striking a balance between fighting drug abuse and upholding legitimate drug use.

GlaxoSmithKline CEO Andrew Witty to retire

GlaxoSmithKline CEO Andrew Witty to retire

Sir Andrew Witty, chief executive officer of GlaxoSmithKline plc, plans to retire from the company next year. GSK announced Witty’s retirement Thursday in releasing its 2015 annual report to shareholders. Plans call for Witty to step down from the CEO post on March 31, 2017.

APhA backs CDC guidelines on opioid prescribing

APhA backs CDC guidelines on opioid prescribing

The American Pharmacists Association (APhA) has voiced its support of final guidelines from the Centers for Disease Control and Prevention (CDC) that aim to help prescribers improve the care and safety of patients being treated for chronic pain.